Genetic Hair and Nail Disorders

Total Page:16

File Type:pdf, Size:1020Kb

Genetic Hair and Nail Disorders Clinics in Dermatology (2005) 23,47–55 Genetic hair and nail disorders Eli Sprecher, MD, PhD* Department of Dermatology and the Laboratory of Molecular Dermatology, Rambam Medical Center, Haifa 31096, Israel Abstract Hair and nails are skin appendages that share with other ectodermal tissues a common developmental pathway. Inherited disorders affecting these two structures therefore very often involve other epithelial components and present with multiple anomalies, generating both physical and psychological distress among patients and their families. The present review briefly describes major recent advances in our understanding of hair and nail genodermatoses. D 2005 Elsevier Inc. All rights reserved. Absence of hair or nails is obviously compatible with tioned in this review are exceedingly rare, genetic testing is normal lifespan, yet patients often experience the loss of often exclusively offered by the research laboratories either one of these two skin appendages as a very investigating those diseases. detrimental condition, affecting many aspects of their personal and social life. In addition, today little relief can be offered to affected individuals. During the last decade, Hair follicle development through the study of rare genetic disorders, much has been learned about the physiology of hair and nail development, Hair follicles start to develop during the 10th week of generating much hope for better and more rationale gestation, when a mesoderm-derived signal induces overly- treatment approaches in the future. A complete discussion ing ectodermal cells to form the primordial hair follicle bud. of all hereditary nail and hair disorders is beyond the scope Subsequently, specialized mesenchymal cells form the of this article. The following review succinctly describes dermal papilla located at the bottom of the growing hair recent and major avenues of research in hair and nail follicles and responsible for generating mesenchymal growth 1 inherited disorders, based on a number of selected exam- and differentiation factors. Competition between various ples. Tables 1-3 present a more exhaustive list of disorders morphogenetic stimulatory (eg, sonic hedgehog) and inhib- for which mutations in specific genes or linkage to specific itory proteins (eg, bone morphogenetic proteins) eventually chromosomal loci have been described. Relevant references determines the final distribution and density of hair fol- 2,3 can be searched for at http://www.ncbi.nlm.nih.gov/entrez/ licles. At birth, about 5 million of hair follicles cover the query.fcgi?db=OMIM. General guidelines for genetic testing body surface and no additional follicles are formed for the various diseases in this article can be found at http:// thereafter. The mature hair follicle, however, continues to www.genetests.org/. Because many of the disorders men- grow in a cyclical fashion, progressing through 3 distinct phases known as anagen (growth phase), catagen (regres- * Tel.: +972 4 8541919; fax: +972 4 8542951. sion phase), and telogen (resting phase). Hair cycling E-mail address: eÀ[email protected]. recapitulates follicular morphogenesis in many aspects 0738-081X/$ – see front matter D 2005 Elsevier Inc. All rights reserved. doi:10.1016/j.clindermatol.2004.09.009 48 E. Sprecher Table 1 Genodermatoses with prominent hair anomalies Disorder Inheritance MIM Locus Gene Isolated hair disorders AUC AR 203655 8p21 HR APL AR 209500 8p21 HR Congenital generalized hyportrichosis XLR 307150 Xq24-q27.1 Unknown Hyportrichosis simplex AD 146520 6p21 CDSN AD 605389 18p11.32 Unknown Localized autosomal recessive hypotrichosis AR 607903 18q12 DSG4 Loose anagen syndrome AD 600628 12q13 K6hf Marie Unna hypotrichosis AD 146550 8p21 Unknown Syndromic hair disorders Androgen insensitivity syndrome XLR 313700 Xq11-q12 AR Argininosuccinicaciduria AR 207900 7cen-q11.2 ASL Bamforth-Lazarus syndrome AR 241850 9q22 FKHL15 Bazex syndrome XLD 301845 Xq24-q27 Unknown Berardinelli-Seip syndrome AR 269700 9q34 AGPAT2 11q13 BSCL2 Biotinidase deficiency AR 253260 3p25 BTD Bjfrnstad syndrome AR 262000 2q34-q36 Unknown Chondrodysplasia punctata XLD 302960 Xp11.23 EBP Cornelia de Lange syndrome AD 122470 3q26.3 NIPBL Carvajal syndrome AR 605676 6p24 DSP Giant axonal neuropathy AR 256850 16q24.1 GAN Griscelli syndrome AR 607624 15q21 MYO5A, RAB27A Hypohidrotic ectodermal dysplasia XLR 305100 Xq12-q13 EDA AD 224900 2q11-q13 EDAR Hypotrichosis with juvenile macular dystrophy AR 601553 16q22.1 CDH3 Hypotrichosis-lymphedema-telangiectasia syndrome AR 607823 20q13.33 SOX18 Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis AR 607626 3q27-q28 CLDN1 Keratosis follicularis spinulosa decalvans cum ophiasis XLR 308800 Xp22.2-22.13 Unknown Keratitis-ichthyosis-deafness syndrome AD 148210 13q11-q12 GJB2, GJB6 Leprechaunism AR 246200 19p13.2 INSR Menkes disease XLR 309400 X12q-q13 ATP7A Naxos disease AR 601214 17q21 JUP NTS AR 256500 5q32 SPINK5 Oculocutaneous albinism, type I AR 203100 11q14-q21 TYR Oculocutaneous albinism, type II AR 203200 15q11.2 P Oculodentodigital dysplasia AD 164200 6q21-q23.2 GJA1 Orofaciodigital syndrome XLD 311200 Xp22.3 CXORF5 Progeria syndrome AD 176670 1q21.2 LMNA Vitamin D–resistant rickets AR 277440 12q12-q14 VDR Waardenburg syndrome I AD 193500 2q35 PAX3 Waardenburg syndrome IIA AD 193510 3p14.1 MITF Werner syndrome AR 277700 8p12-p11.2 RECQL2 because it involves the proliferation and differentiation of Disorders of hair morphogenesis epithelial stem cells in response to dermal papilla-derived signals.4,5 A number of additional anatomical, hormonal, In this group of disorders, abnormal hair is evident at nutritional, and genetic factors further modulate hair shaft birth and persists throughout life. size, shape, and color.1 This developmental scheme forms the basis for the classification of inherited hair disorders Hypotrichosis with juvenile macular dystrophy into disorders of hair morphogenesis, hair cycling, and hair shaft structure. The dual role played by a number of This rare autosomal recessive disorder is characterized by molecules during hair morphogenesis and hair cycling short and sparse hair at birth, which predicts the later accounts for the great deal of overlap existing between the occurrence of progressive macular degeneration (Fig. 1), different groups of hair genodermatoses. eventually leading to blindness during the first to fourth Genetic hair and nail disorders 49 Table 2 Genodermatoses with prominent nail anomalies Disorder Inheritance MIM Locus Gene Isolated nail disorders Isolated congenital nail dysplasia AD 605779 17p13 Unknown Syndromic nail disorders Brachydactyly, type B1 AD 113000 9q22 ROR2 Darier disease AD 124200 12q23-q24.1 ATP2A2 Huriez syndrome AD 181600 4q23 Unknown Nail patella syndrome AD 256020 9q34.1 LMX1B Otopalatodigital syndrome, type I XLD 311300 Xq28 FLNA Pallister-Hall syndrome AD 146510 7p13 GLI3 Pycnodysostosis AR 265800 1q21 CTSK Rubinstein-Taybi syndrome AD 180849 16p13.3 CREBBP Scleroosteosis AR 269500 17q12-q21 SOST Witkop syndrome AD 189500 4p16.1 MSX1 Yellow nail syndrome AD 153300 16q24.3 FOXC2 decade of life.6 Histologically, a high ratio of vellus to pseudomonilethrix.7 Normal hair shaft structure, however, terminal hair as well as a high number of regressing hair has also been observed.6 The disease maps to 16q21, which follicles have been reported. Hair microscopy reveals a harbors a cluster of classical cadherins, the major compo- number of morphological anomalies such as pili torti and nents of adherens junctions. Deleterious mutations have Table 3 Genodermatoses with combined hair and nail anomalies Disorder Inheritance MIM Locus Gene Cartilage hair hypoplasia AR 250250 9p21-p12 RMRP CHILD syndrome XLD 308050 Xq28 NSDHL Coffin-Lowry syndrome XLD 306600 Xp22.2p.22.1 RPS6KA3 Costello syndrome AD 218040 22q13.1 Unknown Dyskeratosis congenita XLR 305000 Xq28 DKC1 AD 127550 3q21-q28 TERC Ectodermal dysplasia – hidrotic type AD 129500 13q11-q12 GJB6 Ectodermal dysplasia – Margarita Island type AR 225060 11q23-24 PVRL1 Ectodermal dysplasia/skin fragility AR 604536 1q32 PKP1 Ellis-van Creveld syndrome AR 225500 4p16 EVC, EVC2 Epidermolysis bullosa AR, AD 131760, 226700, 12q13, 17q12, K5, K14, LAMA3, (simplex, junctional, and dystrophic) 226650, 131750 6q22, 1q25, 3p31.3, LAMB3, LAMC2, 18q11.2, 10q24.3 COL17A1, COL7A1 Hay-Wells syndrome; Ectrodactyly, AD; AD 106260; 129900 3q27 p63 ectodermal dysplasia, and cleft lip/palate syndrome Hereditary bullous dystrophy, macular type XLR 302000 Xq27.3-ter Unknown Incontinentia pigmenti XLD 308300 Xq28 NEMO Lymphedema-distichiasis syndrome AD 153400 16q24.3 FOXC2 Monilethrix AD 158000 12q13 hHb1, hHb6 Naegeli-Franceschetti-Jadassohn syndrome AD 161000 17q11.2-q21 Unknown PC-1/PC-2 AD 167200 12q13 K6a,K6b, K16, K17 167210 17q12-q21 Rothmund-Thomson syndrome AR 268400 8q24.3 REQL4 Sotos syndrome Sporadic 117550 5q35 NSD1 T-cell immunodeficiency, AR 601705 17q11-q12 WHN congenital alopecia, and nail dystrophy Trichodentoosseous syndrome AD 190320 17q21.3-q22 DLX3 Trichorhinophalangeal syndromes AD 190350 8q22-8q24 TRPS1 (EXT1) 150230 190351 Trichothiodystrophy AR 601675 19q13.2-q13.3 TFIIH/XPD 50 E. Sprecher Fig. 1 a, Hypotrichosis of scalp. b, Severe macular pigmentary degenerative changes in a patient with hypotrichosis with juvenile macular dystrophy. been identified in families of various ethnic origins in tions underscore the importance of cell-cell junctions during CDH3, which encodes P-cadherin, a transmembranal hair morphogenesis. classical cadherin
Recommended publications
  • C.O.E. Continuing Education Curriculum Coordinator
    CONTINUING EDUCATION All Rights Reserved. Materials may not be copied, edited, reproduced, distributed, imitated in any way without written permission from C.O. E. Continuing Education. The course provided was prepared by C.O.E. Continuing Education Curriculum Coordinator. It is not meant to provide medical, legal or C.O.E. professional services advice. If necessary, it is recommended that you consult a medical, legal or professional services expert licensed in your state. Page 1 of 199 Click Here To Take Test Now (Complete the Reading Material first then click on the Take Test Now Button to start the test. Test is at the bottom of this page) 5 hr. Nail Structure and Growth & TCSG Health and Safety Outline Why Study Nail Structure and Growth? • The Natural Nail • Nail Anatomy • Nail Growth • Know Your Nails Objectives After completing this section, you should be able to: C.O.E.• Describe CONTINUING the structure and composition of nails. EDUCATION • Discuss how nails grow. • Identify diseases and disorders of the nail All Rights Reserved. Materials may not be copied, edited, reproduced, distributed, imitated in any way without written permission from C.O. E. Continuing Education. The course provided was prepared by C.O.E. Continuing Education Curriculum Coordinator. It is not meant to provide medical, legal or professional services advice. If necessary, it is recommended that you consult a medical, legal or professional services expert licensed in your state. 1 CONTINUING EDUCATION All Rights Reserved. Materials may not be copied, edited, reproduced, distributed, imitated in any way without written permission from C.O.
    [Show full text]
  • Abstract Book
    Abstract Book First World Conference on Ichthyosis August 31 – September 2, 2007 Münster, Germany Organized by Network for Ichthyoses and related keratinization disorders (NIRK) together with Selbsthilfe Ichthyose e.V. and EU-Coordination Action GENESKIN Contacts: H. Traupe, Münster, Email: [email protected] B. Willis, Münster, Email: [email protected] Barbara Kleinow, Email: [email protected] Geske Wehr, Email: [email protected] Location: Lecture Hall Location:Department of Dermatology University Hospital Von Esmarch-Str. 58 48149 Münster Germany Friday, August 31, 2007 page Workshop on clinical diversity and diagnostic standardization D. Metze, Münster Histopathology of ichthyoses: Clues for diagnostic standardization ..................................... 19 I. Hausser, Heidelberg Ultrastructural characterization of lamellar ichthyosis: A tool for diagnostic standardization 13 H. Verst, Münster The data base behind the NIRK register: a secure tool for genotype/phenotype analysis 34 V. Oji, Münster Classification of congenital ichthyosis ................................................................................... 20 M. Raghunath, Singapore Congenital Ichthyosis in South East Asia ............................................................................. 25 Keratinization disorders and keratins I. Hausser, Heidelberg Ultrastructure of keratin disorders: What do they have in common? ................................... 12 M. Arin, Köln Recent advances in keratin disorders .................................................................................
    [Show full text]
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature
    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
    [Show full text]
  • Significant Absorption of Topical Tacrolimus in 3 Patients with Netherton Syndrome
    OBSERVATION Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome Angel Allen, MD; Elaine Siegfried, MD; Robert Silverman, MD; Mary L. Williams, MD; Peter M. Elias, MD; Sarolta K. Szabo, MD; Neil J. Korman, MD, PhD Background: Tacrolimus is a macrolide immunosup- limus in organ transplant recipients. None of these pressant approved in oral and intravenous formulations patients developed signs or symptoms of toxic effects of for primary immunosuppression in liver and kidney trans- tacrolimus. plantation. Topical 0.1% tacrolimus ointment has re- cently been shown to be effective in atopic dermatitis for Conclusions: Patients with Netherton syndrome have children as young as 2 years of age, with minimal sys- a skin barrier dysfunction that puts them at risk for in- temic absorption. We describe 3 patients treated with topi- creased percutaneous absorption. The Food and Drug Ad- cal 0.1% tacrolimus who developed significant systemic ministration recently approved 0.1% tacrolimus oint- absorption. ment for the treatment of atopic dermatitis. Children with Netherton syndrome may be misdiagnosed as having Observation: Three patients previously diagnosed as atopic dermatitis. These children are at risk for marked having Netherton syndrome were treated at different cen- systemic absorption and associated toxic effects. If topi- ters with 0.1% tacrolimus ointment twice daily. Two pa- cal tacrolimus is used in this setting, monitoring of se- tients showed dramatic improvement. All patients were rum tacrolimus levels is essential. found to have tacrolimus blood levels within or above the established therapeutic trough range for oral tacro- Arch Dermatol. 2001;137:747-750 ETHERTON syndrome is taneous absorption of the drug, with serum an autosomal recessive levels well above the therapeutic range.
    [Show full text]
  • A Case of Alopecia Areata in a Patient with Turner Syndrome
    ID Design 2012/DOOEL Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2017 Jul 25; 5(4):493-496. Special Issue: Global Dermatology https://doi.org/10.3889/oamjms.2017.127 eISSN: 1857-9655 Case Report A Case of Alopecia Areata in a Patient with Turner Syndrome Serena Gianfaldoni1*, Georgi Tchernev2, Uwe Wollina3, Torello Lotti4 1University G. Marconi of Rome, Dermatology and Venereology, Rome 00192, Italy; 2Medical Institute of the Ministry of Interior, Dermatology, Venereology and Dermatologic Surgery; Onkoderma, Private Clinic for Dermatologic Surgery, Dermatology and Surgery, Sofia 1407, Bulgaria; 3Krankenhaus Dresden-Friedrichstadt, Department of Dermatology and Venereology, Dresden, Sachsen, Germany; 4Universitario di Ruolo, Dipartimento di Scienze Dermatologiche, Università degli Studi di Firenze, Facoltà di Medicina e Chirurgia, Dermatology, Via Vittoria Colonna 11, Rome 00186, Italy Abstract Citation: Gianfaldoni S, Tchernev G, Wollina U, Lotti T. A The Authors report a case of alopecia areata totalis in a woman with Turner syndrome. Case of Alopecia Areata in a Patient with Turner Syndrome. Open Access Maced J Med Sci. 2017 Jul 25; 5(4):493-496. https://doi.org/10.3889/oamjms.2017.127 Keywords: alopecia areata; Turner syndrome; autoimmunity; corticosteroids; cyclosporine A. *Correspondence: Serena Gianfaldoni. University G. Marconi of Rome, Dermatology and Venereology, Rome 00192, Italy. E-mail: [email protected] Received: 09-Apr-2017; Revised: 01-May-2017; Accepted: 14-May-2017; Online first: 23-Jul-2017 Copyright: © 2017 Serena Gianfaldoni, Georgi Tchernev, Uwe Wollina, Torello Lotti. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
    [Show full text]
  • Chronic Diarrhea in an Adolescent Girl with a Genetic Skin Condition
    PHOTO CHALLENGE Chronic Diarrhea in an Adolescent Girl With a Genetic Skin Condition Lucia Liao, BS; Andrea Zaenglein, MD; Galen T. Foulke, MD A 17-year-old adolescent girl visited our clinic to establish care for her genetic skin condition. She exhibited red scaly plaques and patches over much of the body surface area consistent with atopic dermatitis but also had areas on the trunk with serpiginous red plaques with scale on the leading and trailingcopy edges. She also noted fragile hair with sparse eyebrows. The patient reported that she had experienced chronic diarrhea and abdominal pain since childhood. She asked if it couldnot be related to her genetic condition. WHAT’S THE DIAGNOSIS? a. dyskeratosis follicularis (Darier disease) b. elastosis perforans serpiginosa Doc. erythema marginatum d. Netherton syndrome e. subacute cutaneous lupus erythematosus PLEASE TURN TO PAGE E19 FOR THE DIAGNOSIS CUTIS Ms. Liao is from Pennsylvania State University College of Medicine, Hershey. Drs. Zaenglein and Foulke are from the Department of Dermatology, Pennsylvania State Medical Center, Hershey. Dr. Zaengelin also is from the Department of Pediatrics. The authors report no conflict of interest. Correspondence: Galen T. Foulke, MD, 500 University Dr HU14, Hershey, PA 17033 ([email protected]). E18 I CUTIS® WWW.MDEDGE.COM/DERMATOLOGY Copyright Cutis 2020. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. PHOTO CHALLENGE DISCUSSION THE DIAGNOSIS: Netherton Syndrome
    [Show full text]
  • CORPORATE PRESENTATION Q3 2020 Forward-Looking Statements
    Medicines for Rare Diseases – A Gene Therapy Company CORPORATE PRESENTATION Q3 2020 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (the “Company”), including but not limited to statements about the development of the Company’s product candidates, such as the future development or commercialization of B-VEC, KB105 and the Company’s other product candidates; conduct and timelines of clinical trials, the clinical utility of B-VEC, KB105 and the Company’s other product candidates; plans for and timing of the review of regulatory filings, efforts to bring B-VEC, KB105 and the Company’s other product candidates to market; the market opportunity for and the potential market acceptance of B-VEC, KB105 and the Company’s other product candidates, the development of B-VEC, KB105 and the Company’s other product candidates for additional indications; the development of additional formulations of B-VEC, KB105 and the Company’s other product candidates; plans to pursue research and development of other product candidates, the sufficiency of the Company’s existing cash resources; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the content and timing of decisions made by the U.S.
    [Show full text]
  • Georgia TCSG Health and Safety
    Chapter 1: Georgia TCSG Health and Safety 3 CE Hours Copyright ©October 2002-2015 State of Georgia All rights reserved. Georgia. Developed for the Georgia State Board of Cosmetology No part of this manual may be reproduced or transmitted in any form and the Georgia State Barber Board by the Technical College System or by any means, electronic or mechanical, including photocopying, of Georgia Formerly the Georgia Department of Technical and Adult recording, or by any information storage and retrieval system, Education (DTAE) Publication #C121002, Published December without written permission from the Technical College System of 2002, Revised November 2008. COURSE TABLE OF CONTENTS SECTION 1: SKIN, DISEASES, DISORDERS ● Anatomy and Histology of the Skin ○ Nerves of the Skin ○ Glands of the Skin ○ Nourishment of the Skin ○ Functions of the Skin ○ Terminology ● Diseases and Disorders ○ Skin Conditions/Descriptions ○ Nail Diseases/Disorders ○ Hair Disease/Disorders ○ Skin Conditions/Descriptions SECTION 2: BLOODBORNE PATHOGENS ● What are Bloodborne Pathogens? ● Hepatitis B Virus (HBV) ● Human Immunodeficiency Virus (HIV) ● Signs and Symptoms ● Transmission ● Transmission Routes ● Risk Factors and Behaviors ● Personal Protective Equipment SECTION 3: DECONTAMINATION & STERILIZATION ● Common Questions ● HIV ● Precautions SECTION 4: DECONTAMINATION AND INFECTION CONTROL ● Professional Salon Environment ● Safety Precautions ● Material Safety Data Sheet (M.S.D.S.) ● Organizing an M.S.D.S. Notebook SECTION 5: GEORGIA STATE BOARD OF COSMETOLOGY SANITARY
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]
  • Pili Torti: a Feature of Numerous Congenital and Acquired Conditions
    Journal of Clinical Medicine Review Pili Torti: A Feature of Numerous Congenital and Acquired Conditions Aleksandra Hoffmann 1 , Anna Wa´skiel-Burnat 1,*, Jakub Z˙ ółkiewicz 1 , Leszek Blicharz 1, Adriana Rakowska 1, Mohamad Goldust 2 , Małgorzata Olszewska 1 and Lidia Rudnicka 1 1 Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, Poland; [email protected] (A.H.); [email protected] (J.Z.);˙ [email protected] (L.B.); [email protected] (A.R.); [email protected] (M.O.); [email protected] (L.R.) 2 Department of Dermatology, University Medical Center of the Johannes Gutenberg University, 55122 Mainz, Germany; [email protected] * Correspondence: [email protected]; Tel.: +48-22-5021-324; Fax: +48-22-824-2200 Abstract: Pili torti is a rare condition characterized by the presence of the hair shaft, which is flattened at irregular intervals and twisted 180◦ along its long axis. It is a form of hair shaft disorder with increased fragility. The condition is classified into inherited and acquired. Inherited forms may be either isolated or associated with numerous genetic diseases or syndromes (e.g., Menkes disease, Björnstad syndrome, Netherton syndrome, and Bazex-Dupré-Christol syndrome). Moreover, pili torti may be a feature of various ectodermal dysplasias (such as Rapp-Hodgkin syndrome and Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome). Acquired pili torti was described in numerous forms of alopecia (e.g., lichen planopilaris, discoid lupus erythematosus, dissecting Citation: Hoffmann, A.; cellulitis, folliculitis decalvans, alopecia areata) as well as neoplastic and systemic diseases (such Wa´skiel-Burnat,A.; Zółkiewicz,˙ J.; as cutaneous T-cell lymphoma, scalp metastasis of breast cancer, anorexia nervosa, malnutrition, Blicharz, L.; Rakowska, A.; Goldust, M.; Olszewska, M.; Rudnicka, L.
    [Show full text]
  • ESID Registry – Working Definitions for Clinical Diagnosis of PID
    ESID Registry – Working Definitions for Clinical Diagnosis of PID These criteria are only for patients with no genetic diagnosis*. *Exceptions: Atypical SCID, DiGeorge syndrome – a known genetic defect and confirmation of criteria is mandatory Available entries (Please click on an entry to see the criteria.) Page Acquired angioedema .................................................................................................................................................................. 4 Agammaglobulinaemia ................................................................................................................................................................ 4 Asplenia syndrome (Ivemark syndrome) ................................................................................................................................... 4 Ataxia telangiectasia (ATM) ......................................................................................................................................................... 4 Atypical Severe Combined Immunodeficiency (Atypical SCID) ............................................................................................... 5 Autoimmune lymphoproliferative syndrome (ALPS) ................................................................................................................ 5 APECED / APS1 with CMC - Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) .................. 5 Barth syndrome ...........................................................................................................................................................................
    [Show full text]
  • Pili Torti: Clinical Findings, Associated Disorders, and New Insights Into Mechanisms of Hair Twisting
    CONTINUING MEDICAL EDUCATION Pili Torti: Clinical Findings, Associated Disorders, and New Insights Into Mechanisms of Hair Twisting Paradi Mirmirani, MD; Sara S. Samimi, MD; Eliot Mostow, MD, MPH RELEASERELEASE DATE:DATE: AugustSeptember 2009 2009 TERMINATIONTERMINATION DATE:DATE: AugustSeptember 2010 2010 TheThe estimatedestimated timetime toto completecomplete thisthis activityactivity isis 11 hour.hour. GGOALOAL ToTo understandunderstand primarypili torti tocutaneous better manage nodular patients amyloidosis with the(PCNA) condition to better manage patients with the condition LLEARNINGEARNING OBJOBJECTIECTIVVESES UponUpon completioncompletion ofof thisthis activity,activity, youyou willwill bebe ableable to:to: 1.1. RecognizeDistinguish thepili clinicaltorti from presentation other hair shaftof PCNA. disorders. 2.2. DiscussList conditions the pathophysiology frequently associated of PCNA. with pili torti. 3.3. DistinguishExplain the primarypathophysiologic systemic amyloidosismechanisms from that PCNAcan lead based to pili on torti. clinical and laboratory findings. IINTENDEDNTENDED AAUDIENCEUDIENCE ThisThis CMECME activityactivity isis designeddesigned forfor dermatologistsdermatologists andand generalgeneral practitioners.practitioners. CMECME TestTest andand InstructionsInstructions onon pagepage 107.148. ThisThis articlearticle hashas beenbeen peerpeer reviewedreviewed andand approvedapproved byby CollegeCollege ofof MedicineMedicine isis accreditedaccredited byby thethe ACCMEACCME toto provideprovide MichaelMichael Fisher,Fisher,
    [Show full text]